Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Di

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial] is a phase 2, interventional study registered as NCT07071961 by M.D. Anderson Cancer Center, with a registry enrolment figure of 16 participants, started 2026-02-11 and due to reach its primary completion in 2027-05-01. Interventions recorded: Regorafenib (CT); Lorigerlimab. Conditions listed: Colorectal Cancer; Regorafenib; High Risk Patients. Primary outcome: Safety and adverse events (AEs). Colorectal eligibility wording from the registry: "* History of hysterectomy or bilateral salpingo-oophorectomy". Sites: United States. No results are recorded here; the registry entry is the source.